Pharmacokinetics of Centella Asiatica in the Elderly
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Elderly
- Healthy
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: Randomization will use an arm equivalence design to promote equal numbers of participants for each order schema.Masking: Double (Participant, Outcomes Assessor)Primary Purpose: Screening
Participation Requirements
- Age
- Between 65 years and 85 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: To assess the bioavailability and rate of clearance of Centella asiatica derived compounds in the plasma and urine of cognitively healthy elders over 12 hours. To determine the acute tolerability of a Centella asiatica product in cognitively healthy elders. OUTLINE: Participants ...
PRIMARY OBJECTIVES: To assess the bioavailability and rate of clearance of Centella asiatica derived compounds in the plasma and urine of cognitively healthy elders over 12 hours. To determine the acute tolerability of a Centella asiatica product in cognitively healthy elders. OUTLINE: Participants will orally consume a single administration of a standardized Centella asiatica water extract product (CAP). Two doses (2g and 4g CAW) will be administered on separate occasions, at least two weeks apart. The levels of known bioactive compounds present in Centella asiatica will be measured in human plasma and urine over 12 hours after administration of each of the doses.
Tracking Information
- NCT #
- NCT03929250
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Amala Soumyanath, PhD OHSU Department of Neurology
Get Well Soon